Stiripentol

Introduction Overview

Generic Name

stiripentol

Brand Name

Diacomit

Dosage Form

Capsule; oral powder

Drug Class

Gamma-aminobutyric acid reuptake inhibitors

Pharmacokinetics

Absorption:
Stiripentol is administered orally and is well absorbed from the gastrointestinal tract. The absorption is enhanced when taken with food, hence the recommendation to take Diacomit with meals to optimize bioavailability. The capsule form should be swallowed whole, and for patients unable to swallow capsules, the oral powder can be dissolved in water for immediate consumption. The peak plasma concentration typically occurs within a few hours post-dose, with good systemic availability. Factors such as gastrointestinal motility, presence of food, and patient age may influence absorption rates. Clinical studies indicate consistent plasma levels when dosage is maintained properly.

Distribution:
After absorption, stiripentol exhibits extensive tissue distribution due to its high lipophilicity. It crosses the blood-brain barrier effectively, which is critical for its antiseizure effects in the central nervous system. Plasma protein binding is moderate to high, impacting its distribution volume and interaction with other highly protein-bound drugs. The volume of distribution varies with age and body weight, necessitating dose adjustments in pediatric populations. The drug accumulates in brain tissues, ensuring adequate concentrations at neuronal target sites.

Metabolism:
Stiripentol undergoes extensive hepatic metabolism primarily through cytochrome P450 enzymes, including CYP1A2, CYP2C19, and CYP3A4 isoforms. This metabolism forms multiple inactive metabolites, which are less pharmacologically active but may have potential interactions. Stiripentol is also a known inhibitor of CYP450 enzymes, contributing to its pharmacokinetic interactions with other antiepileptic drugs, especially clobazam. The inhibition can lead to increased plasma levels of concomitant medications, necessitating careful monitoring and often dose adjustments.

Elimination:
Elimination of stiripentol and its metabolites occurs mainly via the renal route, with some biliary excretion. The elimination half-life ranges from 4.5 to 13 hours depending on patient-specific factors like age, organ function, and co-administered drugs. Renal clearance is a significant route for removing metabolites, and hepatic impairment can prolong elimination time. Steady-state plasma concentrations are typically achieved within several days of consistent dosing. Since the drug is eliminated relatively reliably, it allows for twice or thrice daily dosing regimens tailored to patient needs.

Dosage Forms

Available Dosage Forms:
- Oral capsules containing stiripentol (strengths commonly include 250 mg and 500 mg, patient-specific dosing may require combination of different capsule strengths).
- Oral powder packets: each packet is dissolved in water prior to administration, designed for pediatric patients or those unable to swallow capsules.

Dosages for Adults and Adolescents:
- Standard adult dose for Dravet syndrome is 25 mg/kg orally twice daily or 16.67 mg/kg three times daily.
- Maximum total daily dose is capped at 3000 mg.
- The total daily dose corresponds to 50 mg/kg/day.

Specific Patient Populations:
- Pediatric patients aged 6 months to less than 1 year, weighing at least 7 kg: 25 mg/kg twice daily; dosing frequency limited to twice daily to avoid fluid overload and excessive exposure.
- Children 1 year and older weighing 7 to less than 10 kg: recommended 25 mg/kg twice daily with dosing frequency capped at twice daily.
- Children weighing 10 kg or more can be dosed either 25 mg/kg twice daily or 16.67 mg/kg three times daily.
- Dose adjustments may be necessary based on clinical response, weight changes, and presence of side effects, particularly in growing children.
- No monotherapy indication; always to be used concomitantly with clobazam.

Clinical Guidelines:
- Administer capsules whole with a full glass of water during meals.
- Powder form must be dissolved immediately in approximately 3 ounces of water, stirred well, consumed promptly followed by additional fluid intake to ensure full dosage ingestion.
- Dose calculations are weight-based and require regular reassessment with patient growth or weight changes.
- Close clinical and laboratory monitoring advised due to risk of side effects such as weight loss and hematological abnormalities.

Mechanism Of Action

Stiripentol exerts its anticonvulsant effects primarily via modulation of GABAergic neurotransmission, a critical inhibitory pathway in the central nervous system. The drug enhances inhibitory signaling by increasing gamma-aminobutyric acid (GABA) activity, leading to stabilization of neuronal excitability and raising seizure thresholds. Mechanistically, it is believed to inhibit the reuptake of GABA, consequently increasing synaptic GABA concentrations.

On a molecular level, stiripentol acts as a positive allosteric modulator of GABA_A receptors, potentiating their response to endogenous GABA. This modulation leads to prolonged chloride ion channel opening, hyperpolarizing neuronal membranes, and reducing excitatory signaling that contributes to seizure generation. The drug also impacts sodium and calcium channels indirectly through its effect on inhibitory pathways, further stabilizing neuronal activity.

Stiripentol additionally inhibits multiple cytochrome P450 enzymes in the liver, leading to elevated plasma concentrations of concomitant antiepileptic drugs such as clobazam and its active metabolite, N-desmethylclobazam. This pharmacokinetic interaction enhances the overall anticonvulsant effect, making stiripentol an effective adjunct therapy in Dravet syndrome.

Clinical studies and electrophysiological experiments support its synergistic effects when combined with clobazam, contributing to improved seizure control in patients with refractory epilepsies. Compared to other antiepileptics, stiripentol's unique mechanisms targeting both neurotransmitter modulation and metabolic enzyme inhibition underscore its efficacy in severe epileptic syndromes resistant to monotherapy.

Pharmacological Actions

Enhancement of GABAergic inhibitory neurotransmission through GABA reuptake inhibition.
Positive allosteric modulation of GABA_A receptor activity, prolonging chloride channel opening.
Inhibition of cytochrome P450 enzymes (notably CYP1A2, CYP2C19, CYP3A4), leading to increased plasma levels of co-administered drugs.
Adjunctive anticonvulsant effect when combined with clobazam, improving seizure control in Dravet syndrome.
Reduction of neuronal excitability through modulation of synaptic signaling pathways.
Improvement in seizure threshold by balancing excitatory and inhibitory neurotransmission.
Minimal direct effects on sodium or calcium channels but indirect modulation through GABAergic pathways.
Influence on drug metabolism leading to important pharmacokinetic interactions.
Potential neuroprotective effects by stabilizing neuronal electrical activity.
Diminution of seizure frequency and severity in severe, treatment-resistant epilepsies.

Therapeutic Or Clinical Uses

Treatment of seizures associated with Dravet syndrome in adults and children aged 6 months and older.
Adjunctive therapy used in combination with clobazam for enhanced seizure control.
Management of rare, severe epilepsy syndromes characterized by frequent or prolonged seizures.
Reduction in seizure frequency and severity in patients with drug-resistant epilepsy.
Part of multi-drug regimens aiming to improve quality of life in pediatric epilepsy patients.
Used when monotherapy with antiepileptic drugs does not provide adequate seizure control.
Applicable for patients weighing at least 7 kg to ensure safe and effective dosing.
Treatment option for patients unable to tolerate higher doses of clobazam alone due to potentiation by stiripentol.
Beneficial in reducing seizure exacerbations during febrile illness or developmental stages.
Off-label use not supported; strict adherence to use in Dravet syndrome only per current clinical guidelines.

Side Or Adverse Effects

Nausea and vomiting occurring frequently, often dose-dependent.
Loss of appetite leading to significant weight loss, requiring close monitoring especially in children.
Drowsiness and sedation, which may be potentiated by concurrent use of alcohol or other sedating drugs.
Agitation, irritability, and behavioral changes including anxiety and mood disturbances.
Problems with balance and coordination, including tremor and slurred speech.
Muscle weakness potentially affecting motor function.
Sleep disturbances such as insomnia or altered sleep patterns.
Serious hematologic effects including low white blood cell counts increasing infection risk.
Easy bruising, unusual bleeding, and purpura indicating possible hematological toxicity.
Allergic reactions ranging from mild hypersensitivity to severe anaphylaxis.
Presence of suicidal ideation or behavioral changes warranting immediate clinical attention.
Potential liver enzyme elevations to be monitored regularly.
Gastrointestinal discomforts including abdominal pain and diarrhea.
Risk of worsening seizures if the drug is discontinued abruptly.

Precautions

Use only in combination with clobazam for Dravet syndrome; no evidence for monotherapy use.
Avoid abrupt discontinuation to prevent seizure exacerbation; tapering recommended under medical supervision.
Close monitoring of weight and nutritional status, especially in pediatric patients.
Regular hematologic and liver function tests required to detect early adverse effects.
Avoid concomitant use of alcohol or other CNS depressants to reduce excessive sedation.
Inform the physician about all medications, including over-the-counter, vitamins, and herbal products, due to potential interactions.
Use caution in patients with preexisting liver or kidney disease.
Monitor mood and behavior closely for emergence or worsening of psychiatric symptoms.
Pregnancy category: potential fetal harm; use only if benefits outweigh risks and under careful supervision.
Caution advised during breastfeeding; risks and benefits must be evaluated.
Do not exceed recommended dose to avoid toxicity and overdose complications.
Ensure proper hydration when using powder forms to avoid free water overload, especially in infants.
Inform caregivers to monitor for signs of infection or bleeding and to seek medical advice promptly.
Dose adjustments may be necessary based on clinical response and adverse event profile.
Educate patients and caregivers about the importance of adherence to dosing schedules.

Warnings

Potential for severe drowsiness, increased when combined with alcohol or other sedating medications.
Risk of suicidal thoughts or actions; urgent reporting of mood changes required.
Not established as safe or effective for use in children under 6 months or patients weighing less than 7 kg.
Risk of hematological abnormalities including neutropenia and thrombocytopenia.
Avoid driving or engaging in hazardous activities until individual response to the drug is known.
Potential teratogenic effects and fetal harm; pregnancy should be reported and managed carefully.
Weight loss can be significant and impact growth, particularly in pediatric patients.
Sudden withdrawal can provoke increased seizure frequency or severity.
Phenylalanine content in powder form contraindicated in patients with phenylketonuria (PKU).
Interactions with other antiepileptic drugs may necessitate close therapeutic drug monitoring.
Risk of increased bleeding tendency, especially with concurrent anticoagulants or antiplatelet agents.
Patients with history of mood disorders require careful psychiatric monitoring.
Use in hepatic or renal impairment necessitates caution and possibly dose adjustment.
Possibility of hypersensitivity reactions including severe allergic responses.

Contraindication

Hypersensitivity to stiripentol or any components of the formulation.
Children younger than 6 months of age or weighing less than 7 kg.
Patients with phenylketonuria (PKU) due to phenylalanine content in powder form.
Known severe hepatic impairment without careful monitoring and dose adjustment.
Use as monotherapy for Dravet syndrome; lack of clinical data prohibits sole usage.
Concomitant use with drugs contraindicated with CYP450 inhibition that cannot be safely managed.
History of severe hematological disorders that could be exacerbated by the drug.
Use in patients with past suicidal ideation without meticulous psychiatric supervision.
Known allergy to benzodiazepines complicating combination therapy safety.

Drug Interactions

Clobazam: stiripentol increases levels of clobazam and its active metabolite via CYP450 inhibition.
CYP450 substrates: stiripentol inhibits CYP1A2, CYP2C19, CYP3A4 enzymes affecting metabolism of various drugs.
Other CNS depressants (opioids, benzodiazepines, muscle relaxants) may cause additive sedation and respiratory depression.
Anticoagulants and antiplatelet drugs: potentiation of bleeding risk through pharmacodynamic and pharmacokinetic interactions.
Antiepileptic drugs metabolized by CYP enzymes may have altered plasma concentrations.
Medications inducing CYP enzymes can reduce stiripentol efficacy by increasing clearance.
Alcohol increases central nervous system depressive effects and sedation.
Certain antibiotics or antifungals sharing hepatic metabolism pathways may have altered levels.
Vitamins and herbal supplements with CYP enzyme effects require caution.
Medications affecting appetite or weight may have combined effects leading to enhanced weight loss.
Sedative-hypnotics interactions necessitate careful clinical monitoring.
Co-administration of other antiepileptics such as valproate requires dose adjustments due to altered metabolism.
Drugs affecting hematological function may compound risks of blood dyscrasias.
Interaction with oral contraceptives is not documented extensively but caution remains advised.
Use of psychotropic agents with stiripentol should be monitored for behavioral effects and sedation.

Preparations Of The Drug

Capsules available in multiple strengths, typically 250 mg and 500 mg, provided for oral administration.
Powder packets designed for oral suspension, suitable for pediatric patients or patients with swallowing difficulties.
Both capsule and powder formulations intended for dosing during meals to optimize absorption.
Preparations contain excipients including phenylalanine in powder form requiring special consideration in phenylketonuria.
Capsule shells composed of standard pharmaceutical materials allowing for stable gastrointestinal release.
Powder is water-soluble and must be administered immediately after dissolution to ensure dose accuracy.
Packaging designed to protect product from moisture, heat, and light to maintain stability.
Storage recommended at room temperature in a dry place away from direct sunlight.
Available only by prescription and often supplied with detailed dosing instructions and medication guides.
No injectable or intravenous formulations currently available; oral route is the standard and only approved administration method.
Manufactured under Good Manufacturing Practice guidelines ensuring consistent drug potency and purity.
Labeling includes weight-based dosing charts and warnings for specific populations.
Preparation forms are intended to facilitate compliance in pediatric and adult patients alike.
Medication guides highlight the importance of adherence and monitoring during therapy.
Multiple generic versions may be available depending on local regulatory approvals.